Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Status:
Completed
Trial end date:
2018-09-12
Target enrollment:
Participant gender:
Summary
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation
anti-aromatase hormonotherapy in adjuvant or in metastatic line. The Tamoxifen efficacy is
lowered by the hormonoresistance mechanisms due to the primary use of the anti-aromatases.
The Pi3K-AKT-mTor pathway is frequently associated to the hormonoresistance mechanisms. This
study is aimed to check if the inhibition of this signal transduction pathway by a synthetic
mTor inhibitor (Everolimus) could improve the efficacy of the Tamoxifen.